全文获取类型
收费全文 | 21555篇 |
免费 | 5976篇 |
国内免费 | 133篇 |
专业分类
耳鼻咽喉 | 631篇 |
儿科学 | 621篇 |
妇产科学 | 690篇 |
基础医学 | 373篇 |
口腔科学 | 2803篇 |
临床医学 | 4173篇 |
内科学 | 5111篇 |
皮肤病学 | 459篇 |
神经病学 | 1814篇 |
特种医学 | 1034篇 |
外科学 | 4000篇 |
综合类 | 58篇 |
现状与发展 | 12篇 |
预防医学 | 2739篇 |
眼科学 | 323篇 |
药学 | 193篇 |
中国医学 | 6篇 |
肿瘤学 | 2624篇 |
出版年
2024年 | 143篇 |
2023年 | 1090篇 |
2022年 | 366篇 |
2021年 | 646篇 |
2020年 | 1220篇 |
2019年 | 493篇 |
2018年 | 1345篇 |
2017年 | 1295篇 |
2016年 | 1510篇 |
2015年 | 1571篇 |
2014年 | 1979篇 |
2013年 | 2387篇 |
2012年 | 802篇 |
2011年 | 757篇 |
2010年 | 1363篇 |
2009年 | 1957篇 |
2008年 | 758篇 |
2007年 | 513篇 |
2006年 | 664篇 |
2005年 | 495篇 |
2004年 | 351篇 |
2003年 | 309篇 |
2002年 | 282篇 |
2001年 | 411篇 |
2000年 | 305篇 |
1999年 | 400篇 |
1998年 | 505篇 |
1997年 | 488篇 |
1996年 | 538篇 |
1995年 | 393篇 |
1994年 | 303篇 |
1993年 | 260篇 |
1992年 | 178篇 |
1991年 | 159篇 |
1990年 | 139篇 |
1989年 | 145篇 |
1988年 | 128篇 |
1987年 | 129篇 |
1986年 | 101篇 |
1985年 | 98篇 |
1984年 | 79篇 |
1983年 | 93篇 |
1982年 | 83篇 |
1981年 | 68篇 |
1980年 | 47篇 |
1979年 | 34篇 |
1978年 | 34篇 |
1977年 | 43篇 |
1976年 | 33篇 |
1975年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related mortality within the next decade, with limited effective treatment options and a dismal long-term prognosis for patients. Genomic profiling has not yet manifested clinical benefits for diagnosis, treatment or prognosis in PDAC, due to the lack of available tissues for sequencing and the confounding effects of low tumour cellularity in many biopsy specimens. Increasing focus is now turning to the use of minimally invasive liquid biopsies to enhance the characterisation of actionable PDAC tumour genomes. Circulating tumour DNA (ctDNA) is the most comprehensively studied liquid biopsy analyte in blood and can provide insight into the molecular profile and biological characteristics of individual PDAC tumours, in real-time and in advance of traditional imaging modalities. This can pave the way for identification of new therapeutic targets, novel risk variants and markers of tumour response, to supplement diagnostic screening and provide enhanced scrutiny in treatment stratification. In the roadmap towards the application of precision medicine for clinical management in PDAC, ctDNA analyses may serve a leading role in streamlining candidate biomarkers for clinical integration. In this review, we highlight recent developments in the use of ctDNA-based liquid biopsies for PDAC and provide new insights into the technical, analytical and biological challenges that must be overcome for this potential to be realised. 相似文献
6.
7.
8.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
9.
10.